Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]

Kyle, RA; Linos, Athena; Beard, C. Mary; Linke, R. P.; Gertz, MA; O’Fallon, W. Michael; Lt, Kurland

doi:10.1182/blood.v79.7.1817.1817

Cited by 579 publications

(239 citation statements)

References 7 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the use of death certificate data to estimate disease incidence may no longer be valid given survival among amyloidosis patients is improving (Kumar et al, 2011;Parmar et al, 2014;Muchtar et al, 2017). In Olmsted County, Minnesota, the incidence of AL amyloidosis has been estimated to be 8Á9 cases per million person years (Kyle et al, 1992). Given that the Olmsted County population is aging (US Census Bureau, 1990Bureau, , 2016, the incidence may now be higher.…”

Section: Discussionmentioning

confidence: 99%

The epidemiology of amyloidosis in Queensland, Australia

Wisniowski¹,

McLeod

Adams

et al. 2019

Br J Haematol

View full text Add to dashboard Cite

Summary Published studies on the epidemiology of amyloidosis have relied on death certificate data for case ascertainment. We estimated the incidence and mortality burden of amyloidosis among residents of the Australian state, Queensland, aged ≥20 years for the years 1999–2013 based on case ascertainment from histopathology reports. Information systems for participating laboratories were scrutinised to identify histopathology reports that documented a diagnosis of amyloidosis. Case mortality status was determined via linkage to the National Death Index. A total of 447 cases of amyloidosis were identified, with a median age at diagnosis of 66 years. A plasma cell dyscrasia was identified in 72% of patients who had paraprotein studies performed. The estimated incidence for Queenslanders aged ≥20 years was 12·1 cases per million person years. The median survival was 2·45 years. Age at diagnosis, presence of a paraprotein, earlier year of diagnosis, and inner regional location of residence (compared with residence in a major city) were independently associated with reduced survival. Our data confirms previously reported incidence data for amyloidosis of approximately 10 cases per million patient years and indicates that survival for Queensland patients with amyloidosis is improving, though it remains poor for the elderly and patients with AL amyloidosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The epidemiology of amyloidosis in Queensland, Australia

Wisniowski¹,

McLeod

Adams

et al. 2019

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…The usually modest marrow plasma cell clone (the median bone marrow plasma cell infiltrate is 7%) synthesizes structurally abnormal monoclonal light chains (of λ type in 75–80% of the cases) that form amyloid. In Olmsted county, USA, the overall age‐ and sex‐matched annual rate of AL per million persons was 8.9 [73]. The median age at diagnosis in AL‐amyloidosis is about 60 years, with male predominance.…”

Section: Primary Amyloidosismentioning

confidence: 99%

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

Merlini

Westermark

2004

Journal of Internal Medicine

195

136

View full text Add to dashboard Cite

“… * Expected numbers of cases were derived from the age‐ and sex‐matched white population of the Surveillance, Epidemiology and End Results program in lowa (17), except for primary amyloidosis, for which data are from Kyle et al. (18). …”

Section: Monoclonal Gammopathy Of Undetermined Significancementioning

confidence: 99%

MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE

Kyle

Rajkumar

2002

Rev Clin Exp Hematol

View full text Add to dashboard Cite

The term 'monoclonal gammopathy of undetermined significance' denotes the presence of a monoclonal protein in patients without evidence of multiple myeloma, macroglobulinemia, amyloidosis or related plasma cell proliferative disorders. The disorder has been found in approximately 3% of persons older than 70 years and in approximately 1% of persons older than 50 years. A population-based study included 1384 patients from south-eastern Minnesota who had the disorder diagnosed at the Mayo Clinic from 1960 through 1994. Risk of progression was about 1% per year, but patients were at risk of progression even after 25 years or more of stable monoclonal gammopathy of undetermined significance. The risk for development of multiple myeloma was increased 25-fold; the risk of macroglobulinemia, 46-fold; and the risk of primary amyloidosis, 8.4-fold. Concentration and type of monoclonal protein were the only independent predictors of progression. The presence of a urine monoclonal protein and the reduction of one or more uninvolved immunoglobulins were not risk factors for progression. Monoclonal gammopathy of undetermined significance may be associated with various disorders, including lymphoproliferative diseases, leukemia, von Willebrand disease, connective tissue diseases and neurologic disorders.

show abstract

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]

Cited by 579 publications

References 7 publications

The epidemiology of amyloidosis in Queensland, Australia

The epidemiology of amyloidosis in Queensland, Australia

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE

Contact Info

Product

Resources

About